COPENHAGEN, Denmark - July 6, 2006. With the appointment of Dr Søren Bregenholt, 35, as Vice President of Project Management Symphogen strengthens its position as a project-driven, research-based biotech company. The expansion of Symphogen and the many future project activities place great demands on a well-organised matrix organisation. Søren Bregenholt’s participation in executive management is therefore a natural, strategic step toward reinforcing a well functioning and dynamic company:

“Symphogen’s business is to create and commercialize antibody based projects. This is why our project organisation must be represented on the strategic level, where decisions are made. Søren is the right person for the job; he is deeply committed and, indeed, qualified. I’m also very pleased that Symphogen can provide Søren with the opportunity of advancing his career”, says Kirsten Drejer, CEO of Symphogen. 

Prior to his promotion Søren Bregenholt was Director of Project Management and thus was responsible for the implementation of Symphogen’s project organisation. Søren will continue to be part of the daily, operational management of Symphogen’s projects.

About Symphogen
Symphogen’s vision is to develop superior antibody therapeutics by decoding the wisdom of nature. Symphogen was founded in 2000 and is leading in the development of recombinant human polyclonal antibodies that can be used for preventing or treating cancer, serious infectious diseases, and auto-immune disorders. Using its proprietary technologies, Symphogen aims to develop and eventually market unique antibody-based products that mimic the diversity, affinity, and specificity of the natural human immune system. The commercial potential of recombinant human polyclonal antibodies is expected to be significant. It is Symphogen’s long-term objective to establish a dominant position in polyclonal antibody treatment.